Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Leukemia 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 33 Prednisone 28 enzalutamide 19 Abiraterone Acetate 13 pembrolizumab 11 gallium 68 PSMA-11 9 Leuprolide 9 Radiotherapy 8 Pluvicto 8 Magnetic Resonance Spectroscopy 8 Nivolumab 7 Estramustine 7 abiraterone 6 Radiotherapy, Intensity-Modulated 6 Goserelin 6 Carboplatin 6 Biopsy 6 olaparib 5 cemiplimab 5 bicalutamide 5 Specimen Handling 5 Paclitaxel 5 Cyclophosphamide 5 temsirolimus 4 orteronel 4 darolutamide 4 cabazitaxel 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Sirolimus 4 Radiosurgery 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × capivasertib × Clear all

NCT02121639 2022-05-05

ProCAID

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡